Brucella Iron Metabolism in Host Macrophages
宿主巨噬细胞中的布鲁氏菌铁代谢
基本信息
- 批准号:7540938
- 负责人:
- 金额:$ 30.54万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2006
- 资助国家:美国
- 起止时间:2006-02-01 至 2011-01-31
- 项目状态:已结题
- 来源:
- 关键词:AttenuatedAttenuated VaccinesBacteriaBioterrorismBordetellaBrucellaBrucella abortusBrucella melitensisBrucellosisCellsChemistryDevelopmentDiseaseEnvironmentErythrocytesEukaryotaExhibitsGenesGeneticGenomeGoalsGram-Negative BacteriaHemeHeme IronHemoglobinHomologous GeneHumanHydroxyl RadicalIn VitroIronLifeLinkMicrobeMusNaturePhagocytesPhysiologicalPlayProcessProductionProkaryotic CellsProteinsRecyclingRegulationRelative (related person)RepressionResearchResearch PersonnelResistanceRoleShigella dysenteriaeSourceStudy SectionSurveysSystemTestingToxic effectVaccinesVirulenceagedbasecell injurydeprivationexperienceheme ainsightiron metabolismmacrophagemeetingsmicrobialmouse modelmutantnovelpathogenpreventprogramspublic health relevanceresidenceuptakevaccine candidate
项目摘要
Prolonged residence in the phagosomal compartment of host macrophages is critical to the ability of the
Brucella spp. to produce disease. Within this environment, the brucellae must resist iron deprivation. B.
abortus 2308 can utilize heme as an iron source in vitro. Due to the central role of macrophages in the
degradation of erythrocytes and the scavenging of hemoglobin and heme released from damaged cells,
heme may represent an important iron source for the brucellae during their intracellular residence in these
host phagocytes. Two genetic loci (designated bhuA and bhuTUV) whose products are predicted to be
involved in the utilization of heme as an iron source have been identified in B. abortus 2308 and preliminary
characterization of a B. abortus bhuA mutant suggests that this heme transporter plays a critical role in
virulence in mice. Consequently, the specific aims of the studies outlined in this application are a) to confirm
that the products of the genes that we have designated as bhuT, U and Vwork together with BhuA to form a
functional heme transporter in 6. abortus 2308; b) to determine the relative contributions of BhuA and
BhuTUV to the virulence of 6. abortus 2308 in the mouse model; and c) to define the nature of the iron- and
heme-responsive regulation of bhuA and bhuTUV in the B. abortus 2308. The proposed studies should
increase our basic understanding of the mechanisms employed by the Brucella spp. and other intracellular
pathogens to meet their physiologic need for iron in the host. They should also better define the importance
of heme and heme-containing compounds as iron sources for microbial pathogens within this environment.
In addition, these studies should provide insight into the regulatory mechanisms employed by the brucellae
to prevent iron toxicity, which may be different from those used by other Gram-negative bacteria that rely on
the activity of the ferric uptake regulator (Fur). The proposed studies have public health relevance because
they may provide attenuated bacterial strains suitable for testing as novel, live vaccine candidates. Although
the Brucella spp. are important zoonotic pathogens and potential bioterrorism agents, there is presently no
safe and effective vaccine to prevent human brucellosis, and numerous studies have shown that live,
attenuated Brucella strains presently offer the greatest promise for the development of such a vaccine.
宿主巨噬细胞在吞噬体区室中的长期停留对于巨噬细胞的能力至关重要。
布鲁氏菌属从而产生疾病。在这种环境下,布鲁氏菌必须抵抗缺铁。 B.
abortus 2308 可以在体外利用血红素作为铁源。由于巨噬细胞在细胞中的核心作用
红细胞的降解以及受损细胞释放的血红蛋白和血红素的清除,
血红素可能是布鲁氏菌在细胞内居住期间的重要铁源。
宿主吞噬细胞。两个基因位点(称为 bhuA 和 bhuTUV),其产物预计为
已在 B. abortus 2308 中鉴定出参与利用血红素作为铁源的成分,并初步确定
流产 B. abortus bhuA 突变体的表征表明,这种血红素转运蛋白在
对小鼠的毒力。因此,本申请中概述的研究的具体目的是 a) 确认
我们指定为 bhuT、U 和 V 的基因产物与 BhuA 一起形成
6. abortus 2308 中的功能性血红素转运蛋白; b) 确定 BhuA 的相对贡献和
BhuTUV 对小鼠模型中 6. abortus 2308 的毒力; c) 定义铁的性质和
第2308章
增加我们对布鲁氏菌属所采用机制的基本了解。以及其他细胞内
病原体以满足宿主对铁的生理需求。他们还应该更好地定义重要性
血红素和含血红素化合物作为该环境中微生物病原体的铁源。
此外,这些研究应该提供对布鲁氏菌所采用的调节机制的深入了解。
防止铁中毒,这可能与其他依赖铁的革兰氏阴性细菌使用的方法不同
铁吸收调节剂(Fur)的活性。拟议的研究具有公共卫生相关性,因为
他们可以提供适合作为新型活疫苗候选物进行测试的减毒菌株。虽然
布鲁氏菌属是重要的人畜共患病病原体和潜在的生物恐怖分子,目前尚无
安全有效的疫苗可以预防人类布鲁氏菌病,大量研究表明,活疫苗、
目前,减毒布鲁氏菌菌株为开发这种疫苗提供了最大的希望。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ROY M ROOP其他文献
ROY M ROOP的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ROY M ROOP', 18)}}的其他基金
Determining the molecular basis of gene silencing by MucR and defining its role in Brucella virulence
确定 MucR 基因沉默的分子基础并确定其在布鲁氏菌毒力中的作用
- 批准号:
10732605 - 财政年份:2023
- 资助金额:
$ 30.54万 - 项目类别:
Brucellosis 2011 International Research Conference
2011年布鲁氏菌病国际研究会议
- 批准号:
8125631 - 财政年份:2011
- 资助金额:
$ 30.54万 - 项目类别:
Mid-Atlantic Microbial Pathogenesis Meeting(Conference)
大西洋中部微生物发病机制会议(会议)
- 批准号:
6641961 - 财政年份:2003
- 资助金额:
$ 30.54万 - 项目类别:
BRUCELLA STATIONARY PHASE GENE EXPRESSION AND VIRULENCE
布鲁氏菌固定相基因表达和毒力
- 批准号:
6632434 - 财政年份:2000
- 资助金额:
$ 30.54万 - 项目类别:
相似国自然基金
基于mRNA甲基转移酶缺陷的麻疹-腮腺炎联合重组载体疫苗安全性与免疫原性研究
- 批准号:81901679
- 批准年份:2019
- 资助金额:21.0 万元
- 项目类别:青年科学基金项目
基于HA蛋白定点偶联M2e的广谱流感疫苗的研究
- 批准号:31800771
- 批准年份:2018
- 资助金额:27.0 万元
- 项目类别:青年科学基金项目
仿生矿化法提高基因Ⅶ型新城疫活疫苗热稳定性及免疫原性的研究
- 批准号:31700801
- 批准年份:2017
- 资助金额:21.0 万元
- 项目类别:青年科学基金项目
携带神经特异MicroRNA靶序列的重组寨卡减毒株的设计与免疫保护机制研究
- 批准号:31770995
- 批准年份:2017
- 资助金额:60.0 万元
- 项目类别:面上项目
杀鱼爱德华氏菌侵染宿主上皮细胞分子机制研究及靶向侵染关键基因的减毒疫苗设计
- 批准号:31672696
- 批准年份:2016
- 资助金额:25.0 万元
- 项目类别:面上项目
相似海外基金
Host Defense Small Molecule Development for COVID-19 Treatment by Targeting Lysosome
通过靶向溶酶体治疗 COVID-19 的宿主防御小分子开发
- 批准号:
10735492 - 财政年份:2023
- 资助金额:
$ 30.54万 - 项目类别:
Generation of CD8+ Tissue-Resident Memory T cell response during Yersinia pseudotuberculosis foodborne infection
假结核耶尔森菌食源性感染期间 CD8 组织驻留记忆 T 细胞反应的产生
- 批准号:
10572273 - 财政年份:2023
- 资助金额:
$ 30.54万 - 项目类别:
An innovative and straightforward approach to construct and manipulate viral infectious clones
构建和操作病毒感染性克隆的创新且简单的方法
- 批准号:
10667766 - 财政年份:2023
- 资助金额:
$ 30.54万 - 项目类别:
A novel c-di-AMP-based recombinant BCG vaccine
一种新型基于 c-di-AMP 的重组卡介苗疫苗
- 批准号:
10667007 - 财政年份:2023
- 资助金额:
$ 30.54万 - 项目类别:
Investigating the tissue location and protective function of oral vaccine-specific tissue resident memory CD4 T cells
研究口服疫苗特异性组织驻留记忆 CD4 T 细胞的组织定位和保护功能
- 批准号:
10646930 - 财政年份:2023
- 资助金额:
$ 30.54万 - 项目类别: